Objective. Hypoxic perfusion before arrest, an indeterminate period of warm ischemia, and subsequent reperfusion are major causes of cardiac allograft dysfunction in non-heart-beating donors (NHBDs). The present study was undertaken to elucidate the cardioprotective effects of ET A receptor antagonist FR139317 for hearts obtained from asphyxiated NHBDs in a canine transplantation model. Methods. Hypoxic cardiac arrest was induced in 17 donor dogs. FR139317 (10 mg/kg) was given to 7 of the dogs over a period of 10 min before disconnecting the ventilator. The hearts were preserved with FR 139317-supplemented cardioplegic solution (FR group). The remaining 10 did not receive FR 139317 at any time during the experiment (control group). Orthotopic transplantation was performed after a mean myocardial ischemic time of 4 h. Results. During the agonal period, the highest systolic pulmonary artery pressure in the FR group was lower than that in the control group (47 ± 14 vs. 58 ± 27 mmHg). All animals in the FR group were weaned from cardiopulmonary bypass, whereas only five of the controls were weaned, two of which were identified to have dominant right ventricular failure. After transplantation, recovery rates of the left ventricular end-systolic pressure-volume ratio (Emax) and the maximum first derivative of pressure measured over time (max dP/dt) were not significantly different between the groups, but recovery rates of the cardiac index, left ventricular minimum dP/dt and exponential time constant of LV relaxation (tau) in the FR group were higher than those in the control group. Conclusions. The ET A receptor antagonist FR 139317 reduced pressure overload on the right ventricle by decreasing the peak pulmonary artery pressure before donor arrest. Cardioprotective effects of this agent for heart transplantation from NHBDs are manifested by preserved diastolic properties of the left ventricle.
Introduction
Non-heart-beating donors (NHBDs) have been proposed as a means to expand the donor pool for heart transplantation. Because severe myocardial damage during an indeterminate period of warm ischemia and subsequent reperfusion injury are unavoidable, this strategy has not yet been employed beyond the laboratory. Previous studies have demonstrated that death from respiratory arrest in a possible cardiac allograft NHBD results in more severe depletion of myocardial energy stores than death from bleeding.
1 During asphyxiation, global myocardial ischemia due to hypoxic perfusion coupled with endocardial ischemia due to excessive pressure and volume overload during the agonal period may cause metabolic and structural injuries in the whole heart. and pulmonary hypertension. 10,11 Because NHBDs inevitably undergo similar pathological stimuli, endogenous ET-1 could be elevated before and after procurement and might, at least in part, play a deleterious role in transplantation using hearts from NHBDs. In the present study, we investigated the cardioprotective effects of the ET A antagonist FR 139317 for hearts obtained from asphyxiated NHBDs in a canine transplantation model by administering this agent before anoxia as well as by adding it to the cardioplegic solution during preservation.
Materials and methods

Animal preparation
All experimental animals were cared for in accordance with institutional guidelines and the Guide for the Care and Use of Laboratory Animals prepared by the National Academy of Science and published by the National Institutes of Health (NIH Publication 86-23, revised 1985) . The experimental protocol was approved by the Okayama University School of Medicine Experimental Animals Committee. A group of 34 adult mongrel dogs (male and female) weighing 20-33 kg were used. After premedication with ketamine hydrochloride (5 mg/kg) administered intramuscularly, anesthesia was induced with intravenous sodium pentobarbital (5 mg/kg) and intravenous pancuronium bromide (0.2 mg/kg) and maintained with isoflurane inhalation (0.5%-2.0%). The animals were intubated, and mechanical ventilation was begun at an inspired oxygen fraction of 0.5 with a tidal volume of 20 ml/kg and a rate of 12-15 beats/min. The right femoral artery was cannulated for systemic pressure monitoring and blood sampling. A 5F Swan-Ganz catheter was positioned via the right jugular vein in the pulmonary artery to measure cardiac output and to monitor central venous pressure and pulmonary arterial pressure.
Surgical procedure
The chest was entered through a median sternotomy followed by ligation and division of the azygous vein. The heart was suspended by a pericardial cradle. A microtip manometer (model SPC-350; Millar Instruments, Houston, TX, USA) and a conductance catheter (Cordis Europa, Roden, The Netherlands) were introduced into the left ventricle (LV) through the apex. A catheter was inserted into the left atrium to measure pressure. A length of umbilical tape was placed around the inferior vena cava for gradual occlusion to obtain pressure-volume loops. Following systemic administration of heparin (300 IU/kg), asphyxiation was induced by turning the ventilator off. After cardiac arrest was achieved with standstill or ventricular fibrillation, the animals were left for 30 min at room temperature. The inferior vena cava was then transected, and St. Thomas solution (15 ml/kg) at 4°C was infused into the ascending aorta to wash out the coronary beds. The heart was excised and preserved in University of Wisconsin solution at 4°C.
Each recipient dog was then anesthetized and cannulated in a manner analogous to that used for the donor. Cardiopulmonary bypass (CPB) was instituted by bicaval and aortic cannulations. When the esophageal temperature reached 25°C, the ascending aorta was cross-clamped and the recipient's heart was excised. The donor heart was transplanted orthotopically using the biatrial technique. Prior to aortic unclamping, 250 ml of warm blood cardioplegia was infused into the ascending aorta over a 5-min period. Following 60 min of cardiopulmonary support, the animal was weaned from the CPB with an infusion of dopamine (10 µg/kg/min). At the end of the experiment, the animals were killed by intravenous injection of potassium chloride.
Experimental protocol
Seven animals (FR group) received FR139317 (Fujisawa Pharmaceutical, Tsukuba, Japan) at a dose of 6 mg/kg over a period of 10 min before disconnecting the ventilator. This dose was shown to lower the pulmonary artery pressure in a beagle model of pulmonary hypertension.
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For these animals, FR139317 (10 mg/l) was also added to St. Thomas solution to achieve the known concentration for continuous myocardial perfusion during preservation. 12 The remaining 10 animals did not receive FR 139317 at any time during the experiment and served as controls. Donor cardiac function was assessed before induction of anoxia (before pretreatment in the FR group) and 1 h after weaning from CPB at transplantation. Cardiac output was measured by the thermodilu-
